Trial Profile
KRd Consolidation in Myeloma Patients With a Positive PET-CT After Standard First Line Treatment. A Phase II Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Oct 2023
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms CONPET
- 09 Oct 2023 This trial has been discontinued in Sweden, according to European Clinical Trials Database record.
- 04 May 2023 Planned End Date changed from 1 Mar 2025 to 1 Nov 2026.
- 04 May 2023 Status changed from recruiting to active, no longer recruiting.